Arancio Matteo, Ranzoni Stefania, Delsignore Alessandro, Landi Giuseppe, Maffei Nicola, Marcato Maurizio, Mina Alessandro, Martinengo Carlo
ASL "NO". S.C. Urologia. Presidi Ospedalieri di Borgomanero ed Arona, Novara - Italy.
Urologia. 2011 Oct-Dec;78(4):305-9. doi: 10.5301/RU.2011.8307.
2,8-Dihydroxyadenine (DHA) urolithiasis is a rare type of urinary stone disease secondary to deficiency of adenine phosphoribosyltransferase (APRT) activity, a rare, inherited autosomal recessive disease with an incidental rate from 0.4 to 1.2%. The prevalence is higher among Japanese than other ethnic groups. APRT normally catalyzes the conversion of adenine to adenosine monophosphate and its deficiency results in 2,8-dihydroxyadenine (2,8-DHA) accumulation. This compound is extremely insoluble and its crystallization can lead to stone formation and renal failure. We report the case of 2,8-dihydroxyadenine (DHA) urolithiasis in a 52-year-old male patient.
In December 2008 a 52-year-old Caucasian man was admitted to our hospital with sudden pain in the left lumbar region. Abdominal X-ray did not show any radiopaque urinary stone. I.V. pielography showed a radiolucent left lumbar ureteral (0.6 mm) and renal (1.5 cm) stone. After therapy with tamsulosin, the ureteral stone was excreted. Successful ESWL treatment was performed for renal stone. He presented a clinical history of several episodes of bilateral renal colic and two prior ESWL treatment for radiolucent stones. Chemolitholysis was never successful. RESULTS. Stone analysis by infrared spectroscopy and microscopic examination of urine reveal typical 2,8-DHA crystals. APRT deficiency was detected in the hemolysate of erythrocyte. Partial deficiency of APRT in the patient's relatives showed heterozygosity of the enzyme defect. Allopurinol therapy successfully prevented further stone formation. 20 months later the patient remains stone free.
Two types of deficit are commonly distinguished, depending on the level of residual APRT activity. Type I is complete enzyme deficiency. Type II shows residual activity in cell lysates, but enzyme activity is not demonstrable in intact cells. About 78% of the Japanese patients belong to type II. The diagnosis of the disease is based on stone analysis by infrared spectroscopy or microscopic examination of urine, which may reveal typical 2,8-DHA crystals. Molecular approach can identify mutations, which are responsible of this inherited disease. Excessive water intake, restriction of foods with high adenine contents and administration of allopurinol are useful treatments. APRT deficiency is a rare disease but we can consider this pathology in case of recurrent radiolucent stones after chemolitolysis.
2,8 - 二羟基腺嘌呤(DHA)尿路结石病是一种罕见的泌尿系统结石疾病,继发于腺嘌呤磷酸核糖转移酶(APRT)活性缺乏,这是一种罕见的常染色体隐性遗传病,发病率为0.4%至1.2%。在日本人群中的患病率高于其他种族。APRT通常催化腺嘌呤转化为单磷酸腺苷,其缺乏会导致2,8 - 二羟基腺嘌呤(2,8 - DHA)蓄积。这种化合物极难溶解,其结晶可导致结石形成和肾衰竭。我们报告一例52岁男性患者的2,8 - 二羟基腺嘌呤(DHA)尿路结石病。
2008年12月,一名52岁的白种男性因左侧腰部突发疼痛入住我院。腹部X线检查未显示任何不透X线的尿路结石。静脉肾盂造影显示左侧腰部输尿管有一透光结石(0.6毫米)及一枚肾结石(1.5厘米)。服用坦索罗辛治疗后,输尿管结石排出。对肾结石成功进行了体外冲击波碎石术(ESWL)治疗。他有多次双侧肾绞痛发作的病史,之前曾因透光结石接受过两次ESWL治疗。化学溶石治疗均未成功。结果:通过红外光谱法对结石进行分析以及对尿液进行显微镜检查,发现典型的2,8 - DHA晶体。在红细胞溶血产物中检测到APRT缺乏。患者亲属中APRT部分缺乏显示出该酶缺陷的杂合性。别嘌醇治疗成功预防了结石的进一步形成。20个月后患者无结石复发。
根据残余APRT活性水平,通常可区分出两种类型的缺陷。I型为酶完全缺乏。II型在细胞裂解物中显示有残余活性,但在完整细胞中无法证明有酶活性。约78%的日本患者属于II型。该病的诊断基于通过红外光谱法对结石进行分析或对尿液进行显微镜检查,这可能会发现典型的2,8 - DHA晶体。分子方法可识别导致这种遗传病的突变。大量饮水、限制高嘌呤食物摄入以及服用别嘌醇是有效的治疗方法。APRT缺乏是一种罕见疾病,但在化学溶石治疗后反复出现透光结石的情况下,我们应考虑这种病症。